Diphenhydramine IV is NOT appropriate for procedural sedation in children undergoing EEG
Diphenhydramine should not be used as a sedative for pediatric EEG procedures. While the FDA approves IV diphenhydramine for specific indications in children (excluding neonates and premature infants), procedural sedation for diagnostic testing is explicitly NOT among these approved uses 1.
Why Diphenhydramine is Inappropriate for EEG Sedation
FDA-Approved Indications Are Limited
The FDA label clearly restricts IV diphenhydramine use to:
- Allergic reactions when oral therapy is impractical
- Motion sickness treatment
- Parkinsonism when oral therapy is contraindicated
Procedural sedation for EEG is not an FDA-approved indication 1.
Serious Pediatric Safety Concerns
The FDA explicitly warns that in pediatric patients, diphenhydramine may cause:
- Paradoxical excitation rather than sedation (particularly in young children)
- Hallucinations, convulsions, or death in overdosage
- Diminished mental alertness OR excitation (unpredictable response)
- Higher risk of adverse effects in children 1
Guideline-Based Sedation Standards Are Not Met
The 2019 AAP pediatric sedation guidelines 2 establish comprehensive requirements for procedural sedation including:
- Specific monitoring requirements (pulse oximetry, capnography, vital signs every 5-10 minutes)
- Trained personnel skilled in airway management and resuscitation
- Appropriate emergency equipment and rescue medications
Diphenhydramine's unpredictable effects and lack of reversal agent make it unsuitable for controlled procedural sedation where precise depth of sedation must be maintained.
Evidence Comparison
While one small retrospective study 3 compared diphenhydramine to chloral hydrate for EEG sedation, it found:
- Chloral hydrate had higher first-dose success rates
- Chloral hydrate had shorter sleep latency
- Diphenhydramine had more agitation as a complication
- The study itself concluded chloral hydrate was more effective
This research actually argues against diphenhydramine use, despite the authors suggesting further investigation based on cost considerations.
Common Pitfalls to Avoid
- Do not confuse "sedating side effect" with "appropriate sedative agent" - Just because diphenhydramine causes drowsiness doesn't make it suitable for procedural sedation
- Avoid using diphenhydramine simply because it's readily available - Availability doesn't equal appropriateness
- Don't assume antihistamine sedation is "safer" - The unpredictable response (sedation vs. excitation) and lack of reversibility create significant risk
Appropriate Alternatives
For pediatric EEG sedation, consider guideline-concordant agents with:
- Predictable dose-response relationships
- Established safety profiles for procedural sedation
- Available reversal agents when applicable
- Evidence-based protocols (e.g., chloral hydrate, dexmedetomidine, or midazolam under appropriate monitoring)
The bottom line: Use diphenhydramine only for its FDA-approved indications in children. For EEG sedation, select agents specifically validated for procedural sedation with appropriate monitoring and trained personnel as outlined in the AAP guidelines 2.